Placebo News and Research

RSS

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc.

3 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.

1 Dec 2013

Modafinil in combination with antidepressants reduces severity of depression more effectively

A new study has concluded that taking the drug modafinil, typically used to treat sleep disorders, in combination with antidepressants reduces the severity of depression more effectively than taking antidepressants alone.

28 Nov 2013

Researchers show benefits from testosterone administration in hysterectomized women

Hysterectomy and oophorectomy (the removal of ovaries) are performed to treat various diseases in women, including cancer. These procedures are accompanied not only by a decline in estrogen but also testosterone levels in the blood.

27 Nov 2013

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

A study has shown that a daily probiotic drink changed how cells lining the nasal passages of hay fever sufferers reacted to a single out-of-season challenge. However, it did not lead to significant changes in hay fever symptoms, although this challenge test may not have accurately represented natural allergen exposure.

27 Nov 2013

FDA accepts Purdue Pharma's Targiniq ER Tablets CII NDA for review

Purdue Pharma L.P. today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCl controlled-release) Tablets CII, for the management of chronic pain.

27 Nov 2013

Computer-based training programs does not help children with ADHD, says UCF researcher

Many parents spend thousands of dollars on computer-based training programs that claim to help children with ADHD succeed in the classroom and in peer relationships while reducing hyperactivity and inattentiveness. But a University of Central Florida researcher says parents are better off saving their hard-earned cash.

27 Nov 2013

Oxytocin maintains bond between loving couples, promotes monogamy

How is the bond between people in love maintained? Scientists at the Bonn University Medical Center have discovered a biological mechanism that could explain the attraction between loving couples.

26 Nov 2013

Anti-epileptic drugs, bone loss and supplements

Antiepileptic drugs are medications used to prevent and control seizure disorders. These medications are also frequently used for other diagnoses other than seizures, however this current study concentrated on patients with a seizure disorder.

25 Nov 2013

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.

25 Nov 2013

CHMP recommends approval of Otsuka's Deltyba for pulmonary multidrug-resistant tuberculosis

Otsuka Pharmaceutical Co., Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Deltyba (delamanid) in combination with a WHO recommended optimized background regimen for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB). The CHMP opinion will help form the basis for a European Commission decision expected early next year.

25 Nov 2013

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

Janssen-Cilag International NV announced today that the European Commission has approved INVOKANA (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control[1]. Canagliflozin is an oral, once-daily medication, which belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors.

23 Nov 2013

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

23 Nov 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Novel drug combats psychosis in Parkinson’s disease

The non-dopaminergic drug pimavanserin reduces psychotic symptoms in patients with Parkinson’s disease without worsening motor function, shows a randomized trial.

22 Nov 2013

MEMREHAB Trial shows significant effect for cognitive rehabilitation in MS

Kessler Foundation researchers published the results of the MEMREHAB Trial in Neurology, the medical journal of the American Academy of Neurology, providing the first Class I evidence for the efficacy of cognitive rehabilitation in multiple sclerosis. The article, Chiaravalloti N, Moore NB, Nikelshpur OM, DeLuca D: An RCT to treat learning impairment in MS. Neurology 2013(81), was released as an epub ahead of print on November 8

22 Nov 2013

Study reveals benefits of bright light in treating anxiety

The bright light headset maker Valkee today announced the results of a new groundbreaking bright light study, showing statistically significant positive results in acutely alleviating anxiety symptoms. The world's first randomized, fully sham-controlled double blind trial of bright light treatment administered via ear canals brings sought-after new data to support the bright light studies carried out internationally since the 1980s.

21 Nov 2013

UK's first gene therapy trial for patients with chronic heart failure begins at GJNH

The UK’s first gene therapy trial for advanced heart failure, CUPID 2, has officially begun at the Golden Jubilee National Hospital; with the first candidate recently being administered with a dose of the MYDICAR treatment.

21 Nov 2013

BioCardia reports positive results for Transendocardial Autologous Cells in Ischemic Heart Failure Trial

BioCardia, Inc., a leader in cardiovascular regenerative medicine, today announced positive 12-month results for the randomized Transendocardial Autologous Cells (MSC or BMC) in Ischemic Heart Failure Trial (TAC-HFT).

20 Nov 2013

Placebo News and Research

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

Modafinil in combination with antidepressants reduces severity of depression more effectively

Researchers show benefits from testosterone administration in hysterectomized women

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

FDA accepts Purdue Pharma's Targiniq ER Tablets CII NDA for review

Computer-based training programs does not help children with ADHD, says UCF researcher

Oxytocin maintains bond between loving couples, promotes monogamy

Anti-epileptic drugs, bone loss and supplements

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

CHMP recommends approval of Otsuka's Deltyba for pulmonary multidrug-resistant tuberculosis

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Novel drug combats psychosis in Parkinson’s disease

MEMREHAB Trial shows significant effect for cognitive rehabilitation in MS

Study reveals benefits of bright light in treating anxiety

UK's first gene therapy trial for patients with chronic heart failure begins at GJNH

BioCardia reports positive results for Transendocardial Autologous Cells in Ischemic Heart Failure Trial

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News